Pioneering a New Era in Immunotherapy
EnnoDC I About
EnnoDC is a clinical-stage biotech company pioneering the development of first-in-class dendritic cell-targeting CD40 and antigen-specific immunotherapies for cancer and infectious diseases.
EnnoDC I Science
EnnoDC is developing immunotherapies targeting dendritic cells (DCs) with a unique fusion protein composed of an anti-CD40 antibody and tumor-specific or pathogen-derived peptides.
EnnoDC I Pipeline
EnnoDC has a growing pipeline of novel targeted immunotherapies for cancers such as HPV16+ oropharyngeal and prostate cancer, as well as for infectious diseases including HIV and COVID.
Learn More
